EWING, N.J.--(BUSINESS WIRE)--Antares Pharma (AMEX: AIS), Antares announced that the European Medicines Agency (“EMEA”) has provided positive guidance that the current placebo-controlled studies being carried out in the US should be sufficient for a decision regarding European registration of its testosterone Advanced Transdermal Delivery (ATD™) Gel, (known as LibiGel® in the US), which is currently in Phase III Clinical Trials.
